Category - Developments

Developments

Novo Nordisk Foundation investing $200-million for first quantum computer for life sciences research

The Novo Nordisk Foundation has awarded a grant of $200-million to establish the first full-scale quantum computer for the development of new medicines as well as providing new insights into climate change and the green...

September 21, 2022

Developments

MindMed collaborators begin dosing in Phase 1 trial of MDMA-like substances

The first patient has been dosed in a Phase 1 investigator-initiated study led by MindMed (NASDAQ:MNMD; NEO:MMED) collaborator Prof. Dr. Matthias Liechti at University Hospital Basel to evaluate the effects of MDMA-like...

September 20, 2022

Developments

Zucara secures Phase 2 funding for hypoglycemia trial

Closely-held Zucara Therapeutics’ positive proof-of-concept data has enabled the company to secure continued funding for a Phase 2 clinical study of ZT-01 to prevent hypoglycemia in people with Type 1 diabetes, which is...

September 19, 2022

Developments

Profound Medical realigns commercial organization to support continued growth

Profound Medical (NASDAQ:PROF; TSX:PRN) has changed its management team and structure to further position the company for continued sales success and global growth. Abbey Goodman and Hartmut Warnken have been appointed...

September 15, 2022

Developments

FDA clears OpSens SavvyWire for transcatheter aortic valve replacement

OpSens (TSX:OPS; OTCQX:OPSSF) received 510(k) regulatory clearance from the FDA for SavvyWire, its new guidewire for transcatheter aortic valve replacement procedures, or TAVR. In a statement, Louis Laflamme, president...

September 15, 2022

Developments

Sigyn Therapeutics to pursue first-In-human studies in end-stage renal disease

Sigyn Therapeutics (OTCQB:SIGY) plans to pursue first-in-human feasibility studies of its Sigyn Therapy in end-stage renal disease (ESRD) patients suffering from excess inflammation and/or endotoxemia. Sigyn Therapy is...

September 14, 2022

Developments

Hepion collaborators to present new rencofilstat findings in alcohol-related liver disease

Hepion Pharmaceuticals’ (NASDAQ:HEPA) collaborators from London’s Institute of Hepatology will present new findings on Hepion’s cyclophilin inhibitor, rencofilstat, in an awarded oral presentation at the...

September 14, 2022

Developments

Annovis Bio receives additional U.S. patents

Annovis Bio (NYSE:ANVS) announced the publication of three granted U.S. patents that cover methods of treating amyloid lateral sclerosis, Huntington’s disease, and prion diseases by administering buntanetap. The...

September 13, 2022

Developments

Fresh Tracks starts Phase 1 MAD study of DYRK1A inhibitor

Fresh Tracks Therapeutics (NASDAQ:FRTX), formerly Brickell Biotech, initiated the multiple ascending dose (MAD) portion of the ongoing Phase 1 clinical trial in Canada, evaluating FRTX-02, its lead drug candidate, in...

September 13, 2022

Developments

Hepion initiates dosing in Phase 2 ALTITUDE-NASH liver function trial

Hepion Pharmaceuticals (NASDAQ:HEPA) dosed the first stage 3 (F3) NASH subject with rencofilstat in a Phase 2 clinical trial designed to measure hepatic function. The trial is being conducted in collaboration with...

September 12, 2022

Category - Developments

Subscribe